-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Pharmaceutical Group’s Valsartan Amlodipine Tablets (I) Have Been Approved.
Category:
Time：2022-09-26
Recently, Shijiazhuang Fourth Pharmaceutical Group has once again achieved a significant milestone in scientific research and development: its Class 4 chemical drug, Valsartan Amlodipine Tablets (I), has been granted a drug registration certificate by the National Medical Products Administration and is deemed to have passed the evaluation of bioequivalence and therapeutic equivalence for generic drugs.
Recently, Shijiazhuang Fourth Pharmaceutical Group has once again achieved a significant milestone in scientific research and development: the chemical drug of Class 4—Valsartan Amlodipine Tablets (I)—has been granted a drug registration certificate by the National Medical Products Administration and is deemed to have passed the evaluation of consistency in quality and efficacy for generic drugs.
It is reported that Valsartan Amlodipine Tablets (I) are primarily used for the treatment of primary hypertension and for patients whose blood pressure cannot be adequately controlled by monotherapy alone. Hypertension is a common chronic disease, and Valsartan Amlodipine Tablets (I) represent the only single-tablet combination antihypertensive medication included in the National Essential Medicines List. Moreover, this product is the first compound solid dosage form developed by Shijiazhuang Four Pharmaceutical to receive approval. Single-tablet combination formulations have become a new trend in hypertension treatment due to their advantages of reducing the number of pills taken, ease of use, improved treatment adherence, and enhanced efficacy.
In recent years, Shijiazhuang No.4 Pharmaceutical has seen its R&D achievements steadily accumulate and finally come to fruition, providing strong momentum for the company’s competitive advancement and continuously empowering its industrial chain to move toward the high end of the value chain. So far this year, the company has obtained 30 approvals for various products, including 20 approvals for finished dosage forms—a number that leads the industry.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license